RITUXIMAB BIOSIMILAR RTXM83 POST-MARKETING SURVEILLANCE IN BRAZIL: EVALUATION OF THE ADVERSE EVENTS SPONTANEOUSLY REPORTED TO PHARMACOVIGILANCE
Lido
1755
Vezesque se leu este artigo
828
Total PDF
927
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 14 | 9 | 23 |
| 2025 5 | 36 | 14 | 50 |
| 2025 4 | 24 | 15 | 39 |
| 2025 3 | 32 | 11 | 43 |
| 2025 2 | 21 | 17 | 38 |
| 2025 1 | 24 | 18 | 42 |
| 2024 12 | 21 | 12 | 33 |
| 2024 11 | 24 | 24 | 48 |
| 2024 10 | 25 | 15 | 40 |
| 2024 9 | 31 | 16 | 47 |
| 2024 8 | 25 | 22 | 47 |
| 2024 7 | 25 | 22 | 47 |
| 2024 6 | 29 | 24 | 53 |
| 2024 5 | 37 | 27 | 64 |
| 2024 4 | 29 | 15 | 44 |
| 2024 3 | 29 | 16 | 45 |
| 2024 2 | 25 | 22 | 47 |
| 2024 1 | 23 | 18 | 41 |
| 2023 12 | 24 | 25 | 49 |
| 2023 11 | 30 | 29 | 59 |
| 2023 10 | 22 | 25 | 47 |
| 2023 9 | 23 | 21 | 44 |
| 2023 8 | 22 | 23 | 45 |
| 2023 7 | 16 | 11 | 27 |
| 2023 6 | 21 | 6 | 27 |
| 2023 5 | 19 | 16 | 35 |
| 2023 4 | 13 | 9 | 22 |
| 2023 3 | 12 | 13 | 25 |
| 2023 2 | 14 | 16 | 30 |
| 2023 1 | 17 | 6 | 23 |
| 2022 12 | 14 | 15 | 29 |
| 2022 11 | 26 | 20 | 46 |
| 2022 10 | 18 | 19 | 37 |
| 2022 9 | 20 | 31 | 51 |
| 2022 8 | 16 | 23 | 39 |
| 2022 7 | 17 | 24 | 41 |
| 2022 6 | 15 | 23 | 38 |
| 2022 5 | 17 | 21 | 38 |
| 2022 4 | 13 | 20 | 33 |
| 2022 3 | 13 | 26 | 39 |
| 2022 2 | 12 | 15 | 27 |
| 2021 1 | 11 | 14 | 25 |
| 2021 12 | 12 | 21 | 33 |
| 2021 11 | 11 | 22 | 33 |
| 2021 10 | 5 | 17 | 22 |
Mostrar tudo
